Adjuvant Nivolumab + Ipilimumab Lacks Efficacy for Localized RCC
WEDNESDAY, Sept. 14, 2022 -- Disease-free survival (DFS) does not differ with adjuvant nivolumab plus ipilimumab (NIVO+IPI) compared with placebo in patients with localized renal cell carcinoma (RCC) at high risk for postnephrectomy relapse,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Carcinoma | Kidney Cancer | Pharmaceuticals | Renal Cell Carcinoma | Yervoy